These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3309951)

  • 1. New concepts in studying the control of normal and cancer growth of the prostate.
    Coffey DS; Pienta KJ
    Prog Clin Biol Res; 1987; 239():1-73. PubMed ID: 3309951
    [No Abstract]   [Full Text] [Related]  

  • 2. Acceptor sites: genomic sites for androgenic regulation of prostatic growth.
    Rennie PS
    Prog Clin Biol Res; 1987; 239():189-203. PubMed ID: 3309955
    [No Abstract]   [Full Text] [Related]  

  • 3. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells.
    Gao J; Arnold JT; Isaacs JT
    Cancer Res; 2001 Jul; 61(13):5038-44. PubMed ID: 11431338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
    Joseph IB; Nelson JB; Denmeade SR; Isaacs JT
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2507-11. PubMed ID: 9815654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steroid receptors in prostate cancer tissues and cells: pathophysiology, problems in methodology, clinical value and controversial questions.
    Pavone-Macaluso M; Carruba G; Castagnetta L
    Arch Esp Urol; 1994 Mar; 47(2):189-201. PubMed ID: 8002681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of androgen receptor levels: implications for prostate cancer progression and therapy.
    Burnstein KL
    J Cell Biochem; 2005 Jul; 95(4):657-69. PubMed ID: 15861399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The androgen receptor: a potential target for therapy of prostate cancer.
    Santos AF; Huang H; Tindall DJ
    Steroids; 2004 Feb; 69(2):79-85. PubMed ID: 15013685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A critical evaluation of the use of androgen receptor assays to predict the androgen responsiveness of prostatic cancer.
    Barrack ER; Tindall DJ
    Prog Clin Biol Res; 1987; 239():155-87. PubMed ID: 3309954
    [No Abstract]   [Full Text] [Related]  

  • 9. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model.
    Bonkhoff H; Remberger K
    Prostate; 1996 Feb; 28(2):98-106. PubMed ID: 8604398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate.
    Middleman MN; Lush RM; Figg WD
    Pharmacotherapy; 1996; 16(3):376-81. PubMed ID: 8726595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression.
    Agoulnik IU; Vaid A; Bingman WE; Erdeme H; Frolov A; Smith CL; Ayala G; Ittmann MM; Weigel NL
    Cancer Res; 2005 Sep; 65(17):7959-67. PubMed ID: 16140968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.
    Watson PA; Ellwood-Yen K; King JC; Wongvipat J; Lebeau MM; Sawyers CL
    Cancer Res; 2005 Dec; 65(24):11565-71. PubMed ID: 16357166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperactive androgen receptor in prostate cancer: what does it mean for new therapy concepts?
    Culig Z; Hobisch A; Hittmair A; Peterziel H; Radmayr C; Bartsch G; Cato AC; Klocker H
    Histol Histopathol; 1997 Jul; 12(3):781-6. PubMed ID: 9225161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model.
    Cho YM; Takahashi S; Asamoto M; Suzuki S; Tang M; Shirai T
    Prostate Cancer Prostatic Dis; 2007; 10(4):378-83. PubMed ID: 17457304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of flutamide on testosterone metabolism and the plasma levels of androgens and gonadotropins.
    Hellman L; Bradlow HL; Freed S; Levin J; Rosenfeld RS; Whitmore WF; Zumoff B
    J Clin Endocrinol Metab; 1977 Dec; 45(6):1224-9. PubMed ID: 591617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone.
    Culig Z; Stober J; Gast A; Peterziel H; Hobisch A; Radmayr C; Hittmair A; Bartsch G; Cato AC; Klocker H
    Cancer Detect Prev; 1996; 20(1):68-75. PubMed ID: 8907206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer.
    Ho LL; Kench JG; Handelsman DJ; Scheffer GL; Stricker PD; Grygiel JG; Sutherland RL; Henshall SM; Allen JD; Horvath LG
    Prostate; 2008 Sep; 68(13):1421-9. PubMed ID: 18615486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
    Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
    J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine control of prostate cancer.
    Wilding G
    Cancer Surv; 1995; 23():43-62. PubMed ID: 7621473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial comment on: Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.
    Tombal B
    Eur Urol; 2009 Feb; 55(2):321. PubMed ID: 18838209
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.